301 related articles for article (PubMed ID: 37468610)
1. Chimeric antigen receptor T cells march into T cell malignancies.
Tang J; Zhao X
J Cancer Res Clin Oncol; 2023 Nov; 149(14):13459-13475. PubMed ID: 37468610
[TBL] [Abstract][Full Text] [Related]
2. Current state of CAR-T therapy for T-cell malignancies.
Luo L; Zhou X; Zhou L; Liang Z; Yang J; Tu S; Li Y
Ther Adv Hematol; 2022; 13():20406207221143025. PubMed ID: 36601636
[TBL] [Abstract][Full Text] [Related]
3. CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F
Stem Cell Res Ther; 2021 Oct; 12(1):527. PubMed ID: 34620233
[TBL] [Abstract][Full Text] [Related]
4. CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities.
Ren A; Tong X; Xu N; Zhang T; Zhou F; Zhu H
Vaccines (Basel); 2023 Jan; 11(1):. PubMed ID: 36680011
[TBL] [Abstract][Full Text] [Related]
5. CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies.
To V; Evtimov VJ; Jenkin G; Pupovac A; Trounson AO; Boyd RL
Front Immunol; 2022; 13():968395. PubMed ID: 36059451
[TBL] [Abstract][Full Text] [Related]
6. CAR-T Cell Therapy for T-Cell Malignancies.
Testa U; Chiusolo P; Pelosi E; Castelli G; Leone G
Mediterr J Hematol Infect Dis; 2024; 16(1):e2024031. PubMed ID: 38468828
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.
Polgárová K; Otáhal P; Šálek C; Pytlík R
Front Oncol; 2022; 12():876758. PubMed ID: 35600381
[TBL] [Abstract][Full Text] [Related]
8. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells.
Alcantara M; Tesio M; June CH; Houot R
Leukemia; 2018 Nov; 32(11):2307-2315. PubMed ID: 30315238
[TBL] [Abstract][Full Text] [Related]
9. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies.
Chen D; You F; Xiang S; Wang Y; Li Y; Meng H; An G; Zhang T; Li Z; Jiang L; Wu H; Sheng B; Zhang B; Yang L
Am J Cancer Res; 2021; 11(11):5263-5281. PubMed ID: 34873460
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptors for T-Cell Malignancies.
Scherer LD; Brenner MK; Mamonkin M
Front Oncol; 2019; 9():126. PubMed ID: 30891427
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
Cooper ML; DiPersio JF
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.
Abbasi S; Totmaj MA; Abbasi M; Hajazimian S; Goleij P; Behroozi J; Shademan B; Isazadeh A; Baradaran B
Cancer Med; 2023 Apr; 12(7):7844-7858. PubMed ID: 36583504
[TBL] [Abstract][Full Text] [Related]
14. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
Jiang J; Chen J; Liao C; Duan Y; Wang Y; Shang K; Huang Y; Tang Y; Gao X; Gu Y; Sun J
Leukemia; 2023 Aug; 37(8):1660-1670. PubMed ID: 37391486
[TBL] [Abstract][Full Text] [Related]
15. Harnessing the Potential of Chimeric Antigen Receptor T-Cell Therapy for the Treatment of T-Cell Malignancies: A Dare or Double Dare?
Assi R; Salman H
Cells; 2022 Dec; 11(24):. PubMed ID: 36552738
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T-cell therapy for T-ALL and AML.
Wei W; Yang D; Chen X; Liang D; Zou L; Zhao X
Front Oncol; 2022; 12():967754. PubMed ID: 36523990
[TBL] [Abstract][Full Text] [Related]
17. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
Sun W; Liang AB; Huang H; Huang XJ
Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
19. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
20. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
Teoh J; Brown LF
Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]